RACHEL POVILUS: Open Payments
NPI 1750980298 · LONGMONT, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,650 in 107 payments from 19 companies in 2025. Trend: 2023 $3,055 · 2024 $4,542 · 2025 $2,650
Food & beverage: $2,650
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $430 |
| Gilead Sciences, Inc. | 13 | $269 |
| Madrigal Pharmaceuticals | 7 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $191 |
| PFIZER INC. | 5 | $176 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $171 |
| Aimmune Therapeutics, Inc. | 8 | $153 |
| Mirum Pharmaceuticals, Inc. | 1 | $145 |
| GENZYME CORPORATION | 5 | $138 |
| Amgen Inc. | 1 | $132 |
Products named: REZDIFFRA, DUPIXENT, XIFAXAN, ENTYVIO, ZENPEP, Livmarli, VELSIPITY, UPLIZNA.
Industry payments across CO — which companies pay providers there.
